Skip to main content

Advertisement

SpringerLink
Log in

The Role of Cardiovascular Magnetic Resonance for Surveillance of Cardiac Performance upon Receipt of Potentially Cardiotoxic Cancer Therapeutics

  • Myocardial Disease (A Abbate, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Advancements in cancer treatment have resulted in improved cancer-related survival and consequently an increase in the number of cancer survivors. Unfortunately, associated with this increase in cancer-related survivorship, cardiac events have occurred with increasing frequency in cancer survivors. Recognition that cancer survivors are at increased risk for cardiovascular (CV) morbidity has generated interest to develop cardiac imaging techniques that identify subclinical CV disease during receipt of potentially cardiotoxic cancer treatment. Since subclinical cardiovascular disease precedes future cardiac events, early recognition of subclinical CV disease during receipt of potentially cardiotoxic cancer treatment offers the opportunity to initiate strategies that prevent further evolution of subclinical CV disease as well as cardiac events.

Recent Findings

Cardiovascular magnetic resonance imaging (CMR) is an advanced imaging technique that identifies imaging markers of subclinical cardiovascular disease in patients receiving potentially cardiotoxic cancer treatment regimens. In this article, we review the use of CMR for identifying subclinical cardiac disease in patients receiving potentially cardiotoxic cancer treatment regimens.

Summary

The ability of contemporary CMR to accurately define cardiac anatomy, function, and tissue characteristics may represent a critical tool to assess patients with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. https://www.cancer.gov/about-Cancer/understanding/statistics). Access 5 June 2018.

  2. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365–75.

    Article  Google Scholar 

  3. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin’s disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206–14.

    Article  Google Scholar 

  4. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–5.

    Article  CAS  Google Scholar 

  5. Carver JR, et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.

    Article  CAS  Google Scholar 

  6. Silber JH, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820–8.

    Article  CAS  Google Scholar 

  7. Mor-Avi V, Jenkins C, Kuhl HP, et al. Real-time 3-dimensional echocardiographic quantification of left ventricular volumes: multicenter study for validation with magnetic resonance imaging and investigation of sources of error. J Am Coll Cardiol Img. 2008;1:413–23.

    Article  Google Scholar 

  8. Natori S, Lai S, Finn JP, et al. Cardiovascular function in multiethnic study of atherosclerosis: normal values by age, sex, and ethnicity. AJR Am J Roentgenol. 2006;186:S357–65.

    Article  Google Scholar 

  9. Katz J, Millikem MC, Stray-Gunderson J, et al. Estimation of human myocardial mass with MR imaging. Radiology. 1988;169:495–8.

    Article  CAS  Google Scholar 

  10. Katz J, Whang J, Boxt LM, Barst RJ. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. J Am Coll Cardiol. 1993;21:1475–81.

    Article  CAS  Google Scholar 

  11. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–21.

    Article  CAS  Google Scholar 

  12. Semelka RC, Tomei E, Wagner S, et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance imaging studies in the morphologically abnormal left ventricle. Am Heart J. 1990;119:1367–73.

    Article  CAS  Google Scholar 

  13. Pattynama PM, Lamb HJ, van der Velde EA, van der Wall EE, De Roos A. Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Radiology. 1993;187:261–8.

    Article  CAS  Google Scholar 

  14. Plana JC, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.

    Article  Google Scholar 

  15. Drafts BC, Twomley KM, D’Agostino R Jr, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. J Am Coll Cardiol Cardiovasc Imaging. 2013;6:877–85.

    Article  Google Scholar 

  16. Grothues F, Smith GC, Moon JCC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90:29–34.

    Article  Google Scholar 

  17. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol. 2012;110:1679–86.

    Article  CAS  Google Scholar 

  18. •• Jordan J, Hundley WG. Left ventricular mass change after anthracycline chemotherapy. Circ Heart Fail. 2018;11(7):e004560 This study documented a decline in LV mass with Anth B chemotherapy and association of LV mass decline with heart failure symptomatology.

    Article  CAS  Google Scholar 

  19. Ridgway JP. Cardiovascular magnetic resonance physics for clinicians: part I. J Cardiovasc Magn Reson. 2010;12:71.

    Article  Google Scholar 

  20. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57:2263–70.

    Article  CAS  Google Scholar 

  21. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26:493–8.

    Article  Google Scholar 

  22. Sampath S, Derbyshire JA, Atalar E, Osman NF, Prince JL. Real-time imaging of two-dimensional cardiac strain using a harmonic phase magnetic resonance imaging (HARP-MRI) pulse sequence. Magn Reson Med. 2003;50:154–63.

    Article  Google Scholar 

  23. •• Jolly MP, Jordan JH, Meléndez GC, Mcneal GR, D’Agostino RB, Hundley WG. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio- toxic chemotherapy. J Cardiovasc Magn Reson. 2017;19(1):59–62 This study found a strong correlation between cine myocardial strain and left ventricular ejection fraction: r = − 0.61; p = 0.0001.

    Article  Google Scholar 

  24. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42.

    Article  Google Scholar 

  25. Wassmuth R, Lentzsch S, Erdbruegger U, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—a pilot study. Am Heart J. 2001;141(6):1007–13.

    Article  CAS  Google Scholar 

  26. Jordan JH, Vasu S, Morgan TM, D’Agostino RB Jr, Meléndez GC, Hamilton CA, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging. 2016;9(8). https://doi.org/10.1161/CIRCIMAGING.115.004325).

  27. Tham EB, Haykowsky MJ, Chow K, et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson. 2013;15:48.

    Article  Google Scholar 

  28. Neilan TG, Coelho-Filho OR, Shah RV, et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol. 2013;111(5):717–22.

    Article  CAS  Google Scholar 

  29. de Souza TF, Silva TQAC, Osorio Costa F, et al. Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. J Am Coll Cardiol Img. 2018;1045–55.

  30. Hundley WG, Jordan JH. When left ventricular extracellular volume fraction changes after anthracyclines: is it due to a change in the numerator, denominator, or both? J Am Coll Cardiol Img. 2018;11:1056–8.

    Article  Google Scholar 

  31. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with Enalapril and caRvedilolin patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61:2355–62.

    Article  CAS  Google Scholar 

  32. Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101–Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011;11:318.

    Article  Google Scholar 

  33. Chavez-MacGregor M, Clarke CA, Lichtensz-tajn DY, et al. Delayed initiation of adjuvant chemo-therapy among patients with breast cancer. JAMA Oncol. 2016;2:322–9.

    Article  Google Scholar 

  34. Hsieh KP, Chen LC, Cheung KL, et al. Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women—an Asian population-based study. PLoS One. 9:e87027 2014 have each been associated with lower breast cancer survival.

    Article  Google Scholar 

  35. Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, et al. Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) trial. Cardiology. 2012;123:240–7.

    Article  CAS  Google Scholar 

  36. Ingkanisorn WP, Paterson DI, Calvo KR, Rosing D, Schwart zentruber D, Fuisz A, et al. Cardiac magnetic resonance appearance of myocarditis caused by high dose IL-2: similarities to community acquired myocarditis. J Cardiovasc Magn Reson. 2006;8(2):353–60.

    Article  Google Scholar 

  37. Diederichsen LP, Simonsen JA, Diederichsen AC, Kim WY, Hvidsten S, Hougaard M, et al. Cardiac abnormalities assessed by non-invasive techniques in patients with newly diagnosed idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2015;33(5):706–14.

    PubMed  Google Scholar 

  38. Bhatti S, Watts E, Syed F, Vallurupalli S, Pandey T, Jambekar K, et al. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2016;17(9):970–7.

    Article  Google Scholar 

  39. Pozo E, Kanwar A, Deochand R, Castellano JM, Naib T, Pazos-López P, et al. Cardiac magnetic resonance evaluation of left ventricular remodeling distribution in cardiac amyloidosis. Heart. 2014;100(21):1688–95.

    Article  Google Scholar 

  40. Pozo E, Castellano JM, Kanwar A, et al. Myocardial amyloid quantification with look-locker magnetic resonance sequence in cardiac amyloidosis. Diagnostic accuracy in clinical practice and histological validation. J Card Fail. 2017;08:445–53.

    Google Scholar 

  41. Phelan D, Collier P, Thavendiranathan P, et al. Relative “apical sparing” of longitudinal strain using two-dimensional speckle tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442–8.

    Article  Google Scholar 

  42. Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133–42.

    Article  Google Scholar 

  43. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97.

    Article  Google Scholar 

  44. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardio-myopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30:2876–84.

    Article  Google Scholar 

  45. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77–84.

    Article  Google Scholar 

Download references

Funding

This research was supported in part by National Institutes of Health grants R01CA167821, R01CA199167, R01HL118740.

Author information

Authors and Affiliations

  1. Section of Cardiology, Veterans Affairs Medical Center, Salem, VA, USA

    Amitabh Parashar

  2. Virginia Tech Carilion School of Medicine, Roanoke, VA, USA

    Amitabh Parashar

  3. Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

    W. Gregory Hundley

  4. Department of Radiological Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

    W. Gregory Hundley

  5. Department of Internal Medicine, Virginia Commonwealth Health Sciences, Richmond, VA, USA

    W. Gregory Hundley

  6. Department of Radiological Sciences, Virginia Commonwealth Health Sciences, Richmond, VA, USA

    W. Gregory Hundley

  7. Department of Internal Medicine, Section on Cardiovascular Medicine, VCU Health Pauley Heart Center, Virginia Commonwealth University, Gateway bldg. 1200 E Marshall St, Richmond, VA, 23298, USA

    W. Gregory Hundley

Authors
  1. Amitabh Parashar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Gregory Hundley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Gregory Hundley.

Ethics declarations

Conflict of Interest

Amitabh Parashar and W. Gregory Hundley declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This article does not contain any studies with animals performed by any of the authors.

Additional information

This article is part of the Topical Collection on Myocardial Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parashar, A., Hundley, W.G. The Role of Cardiovascular Magnetic Resonance for Surveillance of Cardiac Performance upon Receipt of Potentially Cardiotoxic Cancer Therapeutics. Curr Cardiol Rep 20, 142 (2018). https://doi.org/10.1007/s11886-018-1075-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-018-1075-7

Keywords

Search

Navigation